Prescribing information (external link)
KESIMPTA®▼ (ofatumumab) is indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS) with active disease defined by clinical or imaging features.1
NEXUS 2026: Connecting to Shape the Future of MS Care
Nexus is a two-day promotional meeting (organised and funded by Novartis Pharmaceuticals UK Ltd), designed for the multiple sclerosis (MS) multidisciplinary team, that aspires to enhance the level of care provided by MS Specialists to patients living with MS in the UK by:
Enhancing collaboration among all members of the MS multidisciplinary team (MDT), including consultant neurologists, MS specialist nurses, neurology pharmacists and MS coordinators, to facilitate more cohesive, efficient care for UK patients
Empowering confident, evidence‑based clinical decision‑making that can reduce regional variations in care by equipping the MDT with the latest data, knowledge and practical skills
Equipping MDT members to integrate best practices and apply service‑improvement strategies that raise the standard of care across their service jurisdiction
Agenda
-
10:15 11:00 Hrs
Arrivals, Registration & Networking11:00 11:10 Hrs
Welcome from the Steering Committee11:10 11:40 Hrs
Redefining Multidisciplinary MS Care in 2026 Opening plenary11:40 11:55 Hrs
Q & A11:55 12:30 Hrs
DEBATE: Can Today’s MDT Deliver Tomorrow’s MS Care?12:30 13:30 Hrs
Lunch and Networking13:30 14:15 Hrs
The Modern-Day MDT Workshop14:20 15:20 Hrs
WORKSHOP: Co-creating Solutions for a Real-Life MDT15:20 15:50 Hrs
Break15:55 16:40 Hrs
Service Transformation in the Era of Home-Based Treatments16:40 16:55 Hrs
Closing & Reflections from the Steering Committee -
08:15 08:45 Hrs
Discussing the Impact of ABN in Practice09:00 09:10 Hrs
Welcome from the Steering Committee: Day 209:10 09:40 Hrs
Managing the Rising MS Burden across NHS Neurology Services09:40 09:50 Hrs
Q & A09:55 10:55 Hrs
MS at a Crossroads: Redefining Treatment Goals10:55 11:25 Hrs
Break11:25 12:00 Hrs
Family Planning in MS: An MDT Approach to Supporting Patients*12:00 12:10 Hrs
Q & A12:15 13:15 Hrs
Co-creating Solutions to the Challenges Facing Real-Life MDTs13:15 15:30 Hrs
Reflections & Direction of Travel for MS Care in 2026+15:30 15:30 Hrs
Lunch, Networking & Departures
Steering Committee
Dr Paul Gallagher
Consultant Neurologist, NHS Greater Glasgow & Clyde
Dr Thomas Minton
Consultant Neurologist, Cardiff and Vale University Health Board
Dr Waqar Rashid
Consultant Neurologist, Honorary Clinical Lecturer & Chair of the ABN MS Advisory Group, St. George’s University Hospitals NHS Foundation Trust
Rachel Dorsey-Campbell
Consultant Pharmacist for Neurology and Senior Lead Pharmacist, Imperial College Healthcare NHS Foundation Trust
Carolyn Cairns
MS Advanced Nurse Practitioner and Lead Nurse, The Walton Centre NHS Foundation Trust
Where is NEXUS 2026?
*Women of childbearing potential should use effective contraception while receiving KESIMPTA and for 6 months after the last administration. Treatment with KESIMPTA should be avoided during pregnancy unless potential benefit to the mother outweighs the potential risk to the foetus.1
MDT, multidisciplinary team; MS, multiple sclerosis; Q&A, question and answer; RMS, relapsing forms of multiple sclerosis.
Reference
KESIMPTA (ofatumumab) Summary of Product Characteristics.
UK | March 2026 | FA-11623052
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report, or alternatively email [email protected] or call 01276 698370.
